Phillip Scheinberg

ORCID 0000-0002-9047-4538 OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (8)

3× Hospital A Beneficência Portuguesa, São Paulo, Brazil
2× Division of Hematology Hospital A Beneficência Portuguesa São Paulo Brazil
2× 7Hospital A Beneficência Portuguesa, São Paulo, Brazil
2× Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil
2× 1Hospital A Beneficência Portuguesa, Sao Paulo, Brazil
1× Hospital A, Beneficência Portuguesa, Division of Hematology, São Paulo, Brazil
1× National Institute for Health and Care Research and Wellcome King's Research
1× Hematology, Beneficência Portuguesa, Hospital A, Sao Brésil, Brésil

Papers 13 stored

All · Aachen affiliation only

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies
2025 Annals of Hematology article Immunology and Microbiology Complement system in diseases Open access

1

citations
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
2025 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access

15

citations
Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria
2025 British Journal of Clinical Pharmacology article Immunology and Microbiology Complement system in diseases Open access

10

citations
Essai de phase III randomisé, multicentrique et en ouvert COMMODORE 1 : comparaison du crovalimab et de l’éculizumab chez des patients atteints d’hémoglobinurie paroxystique nocturne (HPN) déjà traités par un inhibiteur du complément
2024 La Revue de Médecine Interne article Immunology and Microbiology Complement system in diseases

0

citations
Incidence, Time to Diagnosis, and Therapeutic Landscape of Aplastic Anemia: Results from a Large United States Claims Database
2024 Blood conference-abstract Medicine Erythropoietin and Anemia Treatment Open access

2

citations
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab
2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access

0

citations
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria
2024 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access

52

citations
Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
2023 Blood conference-abstract Medicine Hemoglobinopathies and Related Disorders

14

citations
MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
2023 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Blood groups and transfusion Open access

2

citations
POSTER: MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
2023 Clinical Lymphoma Myeloma & Leukemia article Medicine Blood groups and transfusion

0

citations
S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
2023 HemaSphere article Immunology and Microbiology Complement system in diseases Open access

5

citations
S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
2023 HemaSphere article Medicine Hemoglobinopathies and Related Disorders Open access

2

citations
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
2022 Blood article Immunology and Microbiology Complement system in diseases

23

citations

13 results